Terms: = Gastric cancer AND AKT1, P31749, RAC-ALPHA, RAC, PRKBA, PKB-ALPHA, PKB, MGC99656, AKT, ENSG00000142208, 207 AND Clinical Outcome
18 results:
1. Oxysterol binding protein-like 3 (OSBPL3) is a novel driver gene that promotes tumor growth in part through R-Ras/akt signaling in gastric cancer.
Hu Q; Masuda T; Koike K; Sato K; Tobo T; Kuramitsu S; Kitagawa A; Fujii A; Noda M; Tsuruda Y; Otsu H; Kuroda Y; Ito S; Oki E; Mimori K
Sci Rep; 2021 Sep; 11(1):19178. PubMed ID: 34584127
[TBL] [Abstract] [Full Text] [Related]
2. NOTCH3, a crucial target of miR-491-5p/miR-875-5p, promotes gastric carcinogenesis by upregulating PHLDB2 expression and activating akt pathway.
Kang W; Zhang J; Huang T; Zhou Y; Wong CC; Chan RCK; Dong Y; Wu F; Zhang B; Wu WKK; Chan MWY; Cheng ASL; Yu J; Wong N; Lo KW; To KF
Oncogene; 2021 Mar; 40(9):1578-1594. PubMed ID: 33452458
[TBL] [Abstract] [Full Text] [Related]
3. MUC16 mutation predicts a favorable clinical outcome and correlates decreased Warburg effect in gastric cancer.
Zhao H; Zhang L
Biochem Biophys Res Commun; 2018 Dec; 506(4):780-786. PubMed ID: 30389134
[TBL] [Abstract] [Full Text] [Related]
4. Telomere Length in Leukocyte DNA in gastric cancer Patients and its Association with Clinicopathological Features and Prognosis.
Tahara T; Tahara S; Horiguchi N; Kawamura T; Okubo M; Ishizuka T; Yamada H; Yoshida D; Ohmori T; Maeda K; Komura N; Ikuno H; Jodai Y; Kamano T; Nagasaka M; Nakagawa Y; Tuskamoto T; Urano M; Shibata T; Kuroda M; Ohmiya N
Anticancer Res; 2017 Apr; 37(4):1997-2001. PubMed ID: 28373473
[TBL] [Abstract] [Full Text] [Related]
5. gastric cancer Patients with High PLK1 Expression and DNA Aneuploidy Correlate with Poor Prognosis.
Otsu H; Iimori M; Ando K; Saeki H; Aishima S; Oda Y; Morita M; Matsuo K; Kitao H; Oki E; Maehara Y
Oncology; 2016; 91(1):31-40. PubMed ID: 27245623
[TBL] [Abstract] [Full Text] [Related]
6. MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.
Venturutti L; Cordo Russo RI; Rivas MA; Mercogliano MF; Izzo F; Oakley RH; Pereyra MG; De Martino M; Proietti CJ; Yankilevich P; Roa JC; Guzmán P; Cortese E; Allemand DH; Huang TH; Charreau EH; Cidlowski JA; Schillaci R; Elizalde PV
Oncogene; 2016 Dec; 35(48):6189-6202. PubMed ID: 27157613
[TBL] [Abstract] [Full Text] [Related]
7. SOX2, a predictor of survival in gastric cancer, inhibits cell proliferation and metastasis by regulating PTEN.
Wang S; Tie J; Wang R; Hu F; Gao L; Wang W; Wang L; Li Z; Hu S; Tang S; Li M; Wang X; Nie Y; Wu K; Fan D
Cancer Lett; 2015 Mar; 358(2):210-219. PubMed ID: 25543086
[TBL] [Abstract] [Full Text] [Related]
8. SphK1 confers resistance to apoptosis in gastric cancer cells by downregulating Bim via stimulating akt/FoxO3a signaling.
Xiong H; Wang J; Guan H; Wu J; Xu R; Wang M; Rong X; Huang K; Huang J; Liao Q; Fu Y; Yuan J
Oncol Rep; 2014 Oct; 32(4):1369-73. PubMed ID: 25109605
[TBL] [Abstract] [Full Text] [Related]
9. clinical significance of racGAP1 expression at the invasive front of gastric cancer.
Saigusa S; Tanaka K; Mohri Y; Ohi M; Shimura T; Kitajima T; Kondo S; Okugawa Y; Toiyama Y; Inoue Y; Kusunoki M
Gastric Cancer; 2015 Jan; 18(1):84-92. PubMed ID: 24615626
[TBL] [Abstract] [Full Text] [Related]
10. Genetic variants in the PI3K/PTEN/akt/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.
Xu JL; Wang ZW; Hu LM; Yin ZQ; Huang MD; Hu ZB; Shen HB; Shu YQ
Asian Pac J Cancer Prev; 2012; 13(5):2157-62. PubMed ID: 22901187
[TBL] [Abstract] [Full Text] [Related]
11. Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer.
Shi J; Yao D; Liu W; Wang N; Lv H; Zhang G; Ji M; Xu L; He N; Shi B; Hou P
BMC Cancer; 2012 Feb; 12():50. PubMed ID: 22292935
[TBL] [Abstract] [Full Text] [Related]
12. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract] [Full Text] [Related]
13. Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Luber B; Deplazes J; Keller G; Walch A; Rauser S; Eichmann M; Langer R; Höfler H; Hegewisch-Becker S; Folprecht G; Wöll E; Decker T; Endlicher E; Lorenzen S; Fend F; Peschel C; Lordick F
BMC Cancer; 2011 Dec; 11():509. PubMed ID: 22152101
[TBL] [Abstract] [Full Text] [Related]
14. gastric cancer in the era of molecularly targeted agents: current drug development strategies.
Arkenau HT
J Cancer Res Clin Oncol; 2009 Jul; 135(7):855-66. PubMed ID: 19363621
[TBL] [Abstract] [Full Text] [Related]
15. Novel interleukin-4 and interleukin-1 receptor antagonist gene variations associated with non-cardia gastric cancer in Japan: comprehensive analysis of 207 polymorphisms of 11 cytokine genes.
Seno H; Satoh K; Tsuji S; Shiratsuchi T; Harada Y; Hamajima N; Sugano K; Kawano S; Chiba T
J Gastroenterol Hepatol; 2007 May; 22(5):729-37. PubMed ID: 17444864
[TBL] [Abstract] [Full Text] [Related]
16. Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127.
Dragovich T; McCoy S; Fenoglio-Preiser CM; Wang J; Benedetti JK; Baker AF; Hackett CB; Urba SG; Zaner KS; Blanke CD; Abbruzzese JL
J Clin Oncol; 2006 Oct; 24(30):4922-7. PubMed ID: 17050876
[TBL] [Abstract] [Full Text] [Related]
17. akt/pkb activation in gastric carcinomas correlates with clinicopathologic variables and prognosis.
Nam SY; Lee HS; Jung GA; Choi J; Cho SJ; Kim MK; Kim WH; Lee BL
APMIS; 2003 Dec; 111(12):1105-13. PubMed ID: 14678019
[TBL] [Abstract] [Full Text] [Related]
18. Postoperative outcome and sites of recurrence in patients following curative resection of gastric cancer.
Maehara Y; Hasuda S; Koga T; Tokunaga E; Kakeji Y; Sugimachi K
Br J Surg; 2000 Mar; 87(3):353-7. PubMed ID: 10718807
[TBL] [Abstract] [Full Text] [Related]
